Clinical trials of combinations of adhesion inhibitors and chemotherapy for AML.
|Title||Clinicaltrials.gov designation||Institution or sponsor|
|Study of plerixafor combined with cytarabine and daunorubicin in patients with newly diagnosed acute myeloid leukemia||NCT00990054||Multicenter-Genzyme-Sanofi|
|First in human study to determine the safety, tolerability, and preliminary effectiveness of MDX-1338 (BMS936564) in subjects with acute myelogenous leukemia (AML)||NCT01120457||Multicenter-Bristol-Myers Squibb|
|Granulocyte colony-stimulating factor (G-CSF) and plerixafor plus sorafenib for acute myelogenous leukemia (AML) with FLT3 mutations||NCT00943943||MD Anderson Cancer Center|
|Chemosensitization with plerixafor plus G-CSF in acute myeloid leukemia||NCT00906945||Washington University|
|IV plerixafor with mitoxantrone etoposide and cytarabine for acute myeloid leukemia (AML)||NCT01027923||Washington University|
|Plerixafor and clofarabine in frontline treatment of elderly patients with acute myelogenous leukemia (AML)||NCT01160354||MD Anderson Cancer Center|